"Ah, try 12 and it's fine. The problem is not getting the booster."
Forget the BOOOOOSTER ...................... earn a bit of cash and do this experimental drug as Advertised here on HC.Source:Adobe Stock
Sydney-based drug development companyNyrada Inc (ASX:NYR)has completed anin vivomicronucleus study on rats which has supported expectations of safety for its NYR-BI03 drug candidate – particularly in terms of genetic damage – ahead of Phase 1 human trials later this year.
The study – completed as part of Nyrada’s brain injury program Good Laboratory Practices (GLP) – found there was no increase in markers of genotoxicity in treated animals compared with control treated animals.
